Revise Notes Cardio Flashcards

1
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Acs

A

Background

The term Acute coronary syndrome (ACS) encompasses a spectrum of myocardial ischaemic disease, including:

STEMI – Presence of classical ECG changes (ST elevation/ LBBB) and positive biochemical markers (troponins)

NSTEMI – Absence of ST elevation but positive biochemical markers +/- other ECG changes (such as T wave inversion)

Unstable angina – myocardial ischaemia without infarction - negative troponins, worsening angina symptoms including at rest/minimal exertion.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

NICE Guidelines: Management of Unstable Angina and NSTEMI

Excellent NICE visual summary: https://www.nice.org.uk/guidance/ng185/resources/visual-summary-unstable-angina-nstemi-pdf-8900622109

The initial management steps of unstable angina (UA) and NSTEMI are generally the same. Certain interventions are then implemented on a risk basis.

A

Risk assessment

The most commonly used tool to assess a patient’s risk is the GRACE score.

The GRACE score formally assesses the risk of future cardiovascular events and 6-month mortality rate. Risk factors include:

Age, heart rate, systolic BP, creatinine
Cardiac enzymes, presence of ST elevation on ECG, cardiac arrest on admission

Killip class (signs of HF)
1. No evidence of HF
2. Crepitations / S3
3. Frank pulmonary oedema
4. Cardiogenic shock

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Management ACS

A

Step 1: Antiplatelets

1st Antiplatelet - Give Aspirin 300mg loading, continue indefinitely
Dual antiplatelets: Depends on risk (GRACE) - see below

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Acs mng

A

Step 2: Antithrombin

Thrombin is the enzyme which converts fibrinogen into fibrin - an integral step in clot formation.

There are 2 main antithrombin treatment options - fondaparinux or unfractioned heparin

  1. Fondaparinux

Offer fondaparinux to all patients, unless undergoing immediate coronary OR high risk of bleeding.
2. Unfractionated Heparin (UFH)

Indications for UFH:
Significant renal impairment – Creatinine > 265
High bleeding risk: CKD, old age, low body weight, relevant comorbidities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Acs mng

A

Step 3: Further Management - Conservative vs early invasive approach

Unstable condition

Offer immediate coronary angiography

Intermediate/high risk - GRACE > 3% - Early invasive approach:

Perform coronary angiography (+/- PCI) within 72 hours
Second antiplatelet:
Prasugrel or ticagrelor (with aspirin as DAPT)
OR clopidogrel (with aspirin as DAPT) if they have a separate indication for ongoing PO anticoagulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Acs mng

A

Low risk - GRACE < 3% - Conservative approach

Consider functional imaging before discharge
If inducible ischaemia, proceed to coronary angiography +/- PCI

Second antiplatelet:
Offer ticagrelor (with aspirin as DAPT)
If high bleeding risk, use clopidogrel (with aspirin as DAPT) instead

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

NICE Guidelines: Management of STEMI

Diagnostic criteria: ST-elevation in 2 or more contiguous leads or new LBBB

Excellent NICE visual summary: https://www.nice.org.uk/guidance/ng185/resources/visual-summary-stemi-pdf-8900623405

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Management of STEMI

A
  1. Antiplatelets

Single loading dose of aspirin 300mg
Second antiplatelet (DAPT) - Various options..

Having PCI
Prasugrel if not taking an oral anticoagulant

Or ticagrelor or clopidogrel if high bleeding risk

Clopidogrel if taking an oral anticoagulant

NOT having PCI - ticagrelor OR clopidogrel if high bleeding risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q
  1. Coronary reperfusion therapy

Mng of stemi

A

Is primary PCI possible in < 120 minutes? AND presentation within 12 hours - YES

Primary PCI

Patients with STEMI should be offered angiography + PCI if they present within 12 hours of symptom onset and primary PCI can be performed within 2 hours.

Also consider if late presentation (>12hrs) but continuing ischaemia or shock.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Is primary PCI possible in < 120 minutes? NO

A

If PPCI is not possible in < 120 minutes, treat with fibrinolysis.

Fibrinolytic drugs: alteplase, streptokinase, tenecteplase or reteplase

Also give an antithrombin at the same time (fondaparinux/UFH)
Repeat ECG

Repeat ECG 60 – 90 minutes following fibrinolysis.

If there is residual ST elevation (>50%) - immediate coronary angiography + PCI.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Post-MI Complications

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Secondary Prevention

All patients should be treated with the following:

A

Cardiac rehabilitation program

Dual antiplatelet therapy
Aspirin 75mg OD for life

Second antiplatelet depends on management - ticagrelor, clopidogrel etc.

In patients with other vascular disease (stroke/peripheral arterial disease), after one year of DAPT, clopidogrel (not aspirin) should be continued.

In patients who take a NOAC, use single antiplatelet therapy

ACE inhibitor (ARB if not tolerated)
Beta blocker
High dose statin
Aldosterone antagonist for HFrEF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Post-MI Complications

A

Ventricular Fibrillation - the most common cause of death post-MI

Arrhythmias – especially AV block in those following an inferior MI (RCA)

Pericarditis
Within 2-3 days – pain on lying flat, pericardial rub on auscultation, pericardial effusion on echo

Dressler’s syndrome
An autoimmune process. Differentiated from pericarditis by delayed onset
Occurs at 4-6 weeks – suggested by fever, pleuritic chest pain, raised ESR, pericardial effusion.
Manage with NSAIDs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Post-MI Complications

A

Left ventricular aneurysm
Suggested by persistent ST elevation and symptoms of left ventricular failure.
Treat with NOAC (reduce risk thrombosis)

LV free wall rupture
Occurs at 1-2 weeks
Presents with cardiac tamponade (Beck’s triad of acute HF, raised JVP, quiet heart sounds)
Management: Urgent pericardiocentesis and thoracotomy

Ventricular septal defect
1-2 weeks post MI
Harsh pansystolic murmur

Mitral regurgitation
Papillary muscle rupture - pansystolic murmur, heart failure and hypotension

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Acute limb ischaemia
Key learning

Acute limb ischaemia: Rapid revascularization within 6 hours is crucial to prevent tissue necrosis.

Clinical features: 6Ps—pale, pulseless, painful, perishingly cold, paralysed, paraesthesia.

A

Investigations: If time allows then CT/MRI angiography to differentiate thrombosis from embolism.

Management:
Initial—ABCDE, high-flow oxygen, IV heparin, inform vascular team.

Operative—thrombolysis, angioplasty, embolectomy, or bypass.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Acute limb ischaemia
Pathophysiology

A

1) Thrombotic occlusion of diseased vessel

OR

2) Embolisation from a distant site

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Acute limb ischaemia

A

Definitions

Acute
Previously stable limb with sudden deterioration in arterial supply in < 14 days

Acute on chronic
Worsening signs/symptoms over last 14 days

Chronic
Ischaemia stable for > 14 days

Critical limb ischaemia
Persistent rest pain or tissue loss (Fontaine Stage 3 or 4)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Acute limb ischemia causes

A
  1. Thrombosis

60%
Less severe as collateral vessels

  1. Embolism

30%
Cardiac origin- most common
AF
Mural thrombus post MI

Arterial origin
Aortic/femoral/popliteal aneurysm

Venous origin- rare
Patent foramen ovale

Iatrogenic
Post surgery/angioplasty

Cholesterol emboli
Following long bone fracture

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Acute limb ischemia causes

A
  1. Trauma

Compression/dissection of artery or compartment syndrome (see separate section on compartment syndrome)

Most common sites:
Supracondylar humerus fracture
Posterior knee dislocation
Post-vascular surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Clinical features

6Ps

A

6Ps

Pale
Pulseless
Painful
Perishingly cold
Paralysed (later on)
Paraesthetic (later on)

Others:
Pain on passive movement of squeezing calf (later on and not part of 6Ps)

Non-viable limb signs:
Fixed mottling- Non-blanching colour changes in leg
Rigid muscles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Investigations acute limb ischemia

Pre-op:

A

Bloods:

Hb
Ischaemia worsened if anaemic
Clotting and G&S/X-match
As operative intervention likely

UEs
Acute ischaemic limb is associated with renal artery stenosis/ rhabdomyolysis
Glucose/lipids
Underlying cardiovascular risk factors

ABG
Lactate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
26
INV pre op acute limb ischemia
ECG Underlying AF Pre-op CT/MRI angiography Only if time allows Can differentiate thrombosis from embolism Intra-arterial digital subtraction angiography Gold standard but rarely used
27
Post op assessment Acute limb ischemia
Post op (assessing cause): Echo Patent foramen ovale- venous embolism Ultrasound Aortic/femoral/popliteal arteries- arterial embolism
28
Management Limb-threatening event Need revascularisation within 6 hours to avoid necrosis distally
Initial management A to E assessment NBM Involve senior/vascular team early and urgently High flow oxygen Dual IV access (wide-bore) IV fluid whilst NBM Analgesia Morphine Anticoagulation IV heparin- bolus and infusion Monitor APTT (consult haematology, often aim 2-2.5x normal range
29
Operative management Vascular surgeon will assess if surgery indicated and timing Severity by Rutherford Classification Acute limb ischemia
If thrombosis: Thrombolysis Angioplasty +/- stenting Emergency bypass/reconstruction If embolism: Embolectomy Anticoagulation If limb is not viable in either case: Amputation Post-op: Investigate for underlying cause i.e. echo Manage cardiovascular risk factors i.e. statin, anti-platelet, BP control
30
Complications post-op Acute limb ischemia
: Reperfusion injury Inflammation / oxidative damage when blood flow restores to tissue following prolonged period of reduced oxygen supply Can result in: Oedema Compartment syndrome Acidosis Arrhythmias (due to hyperkalaemia) ARDS GI oedema- can cause endotoxic shock Acute kidney injury- build up of toxic metabolites during the ischaemic episode which then re-enter blood stream Compartment syndrome See separate note
31
Useful links Rutherford Classification BMJ Best Practice - Peripheral arterial disease NICE CKS Peripheral arterial disease Geeky Medics- Rutherford Classification
Useful links Rutherford Classification BMJ Best Practice - Peripheral arterial disease NICE CKS Peripheral arterial disease Geeky Medics- Rutherford Classification
32
Thrombosis vs Embolism
Thrombosis: Slower onset (hours to days) Less severe as collaterals Claudication present Contralateral pulses often absent (as more likely acute on chronic) Thrombosis can be seen on angiography Management: Thrombolysis Bypass surgery
33
Embolism
Embolism: Sudden onset Profound ischaemia (more severe) No claudication history Present collateral pulses More clinical diagnosis (investigations less useful) Management: Embolectomy Anticoagulation
34
Angina Pectoris
Background The term angina describes the pain occurring secondary to cardiac ischaemia when coronary blood flow (and hence oxygen supply) does not meet cardiac demand. This is most commonly caused by atherosclerotic narrowing of the coronary arteries, and is precipitated by exertion and the associated increased oxygen requirement of the heart. Angina can be categorised as..
35
Stable and unstable angina
Stable - occurring in a stable, predictable pattern - precipitated by exertion and relieved by rest/GTN. Lasting < 10 minutes. Unstable - new onset angina/a deterioration in pre-existing anginal symptoms Requires urgent admission. Suspect UA if: Pain at rest or on minimal exertion Rapidly progressive/deteriorating anginal pain (e.g. increasing frequency)
36
Initial Assessment NICE advise the following approach when assessing possible angina.
Step 1: Categorise chest pain as typical, atypical or non-anginal according to the following clinical features: Constricting discomfort affecting the chest, arms or neck Symptoms precipitated by exertion Symptoms relieved within 5 minutes use of GTN or rest Typical chest pain – 3/3 features Atypical chest pain – 2/3 features Non-anginal chest pain – 1 or 0/3 If Non-anginal AND no significant risk factors – angina excluded If unable to rule out angina - i.e. atypical, typical history OR ECG changes OR risk factors - investigate as below (consider prescribing aspirin until diagnosis excluded)
37
Investigations of angina IST line
Basic investigations for all patients: FBC + ECG +/- CXR if indicated 1st Line: CT coronary angiogram (CTCA) Diagnosis of significant coronary artery disease made if: 70% stenosis of 1 major coronary artery OR 50% stenosis of the left main coronary artery
38
2nd line investigation Angina
2nd line: If CTCA is inconclusive/ patient already has a known diagnosis of CAD: Non-invasive functional imaging - to demonstrate reversible/inducible ischaemia Cardiac MRI (+ stress - dobutamine/exercise) Myocardial perfusion scan with SPECT Stress echocardiography Exercise ECG – only if known coronary artery disease
39
A diagnosis of stable angina is confirmed when there is evidence of:
significant CAD on CTCA or.. Reversible myocardial ischaemia on non-invasive functional imaging
40
Angina 3rd line investigation
3rd line: Invasive coronary angiography
41
Management of Angina Pectoris
Basic Management All patients should be given Statin Aspirin 75mg OD for secondary prevention GTN – if angina persists despite 2 x doses – call 999 ACEi if any of - diabetes, HTN, HF, CKD or MI Consider SGLT2i if DM
42
Stepwise Management of Angina
1st line: B-blocker (bisoprolol) or calcium channel blocker (rate limiting CCBs (verapamil, diltiazem) are preferred to dihydropyridines) Titrate to the maximum tolerated dose Tip: Caution with B-blockers and asthma – in which case a RLCCB may be preferred due to risks of bronchospasm. 2nd line: B-blocker PLUS Calcium channel blocker If already taking a beta blocker: Add a long-acting dihydropyridine CCB (amlodipine, MR nifedipine/felodipine) If taking a dihydropyridine CCB: Add a beta-blocker
43
Do NOT co-prescribe B-blocker and rate limiting-CCB (risk of complete heart block, severe bradycardia and HF) - use a dihydropyridine instead (MR nifedipine, MR felodipine, amlodipine
Do NOT co-prescribe B-blocker and rate limiting-CCB (risk of complete heart block, severe bradycardia and HF) - use a dihydropyridine instead (MR nifedipine, MR felodipine, amlodipine
44
If either of the second line drugs is contraindicated or if the patient is on monotherapy (i.e. because they didn’t tolerate BB/CCB etc.) then add one of the following alternatives:
Long acting nitrate - Isosorbide mononitrate (ISMN) Ivabradine Nicorandil Ranolazine
45
3rd line Angina
If the patient is on dual therapy (tolerating both BB and CCB), refer to cardiology for angiography +/- revascularisation if required (PCI/CABG) CABG is preferred over PCI if the patient is diabetic/ >65yrs/ has triple vessel disease - proven survival benefits Only consider adding a 3rd drug (from above list) whilst awaiting specialist review.
46
Ischaemic heart disease - Pharmacology Nitrates
Mechanism of Action: Induce NO release by smooth muscle --> increased c. GMP --> Decreased intracellular calcium levels = vasodilation Side effects: Hypotension, tachycardia, flushing, headaches, reflux Tolerance: does NOT occur if we use modified release nitrates
47
Ivabradine
Mechanism: Inhibits the funny (If) current channels in the sinoatrial node (SAN) --> reduced heart rate. Side effects: Luminous phenomena (halos/coloured bright lights/stars), bradycardia Tip: Funny current inhibitors - Funny vision Peripheral oedema/ankle swelling
48
Antithrombins
Enoxaparin and fondaparinux – activates AT3 – inhibits factor Xa Bivalirudin – direct thrombin inhibitor References & Further Reading: National Institute for Health and Care Excellence [NICE] (2022). Angina. https://cks.nice.org.uk/topics/angina/ - Revised June 2023
49
50
51
52
53
54
55
56
57
Definition and pathophysiology of AAA
Definition Abnormal localised dilatation of vessel of over 50% of normal diameter Aortic aneurysm = 3cm or above Pathophysiology A weakening of the aortic wall leads to bulging or dilation, predisposing to rupture All three layers of vessel involved (less = pseudo-aneurysm) Commonly involves the abdominal aorta (AAA) - most commonly infrarenal
58
Aortic Aneurysm Key learning
Definition: 3cm or more dilation of all layers of vessel Commonly involves the abdominal aorta (AAA) - most commonly infrarenal Risk factors: Older men who have hypertension and smoke Symptoms: Often none until rupture, abdominal pain radiating to back Screening programme: One off scan for all men over 65 Management: If > 5.5cm or growing 1cm/yr or symptomatic- EVAR or open elective surgery Ruptured AAA confers 75% mortality and requires immediate resuscitation and open emergency surgery to repair
59
Complications Ruptured AAA
Stabilise if in shock- major haemorrhage protocol Portable USS (CT only if stable) Urgent surgical repair - usually open repair 75% mortality Other complications Embolisation- causes femoral artery thrash and acute limb ischaemia Direct pressure- compressed nearby structures including duodenem, ureters or IVC Useful links NICE guidelines- Abdominal aortic aneurysm: diagnosis and management
60
Management of AAA
As per screening programme: Elective AAA repair EVAR preferred to open repair as lower post-op mortality and reduced length of stay If not fit for surgery: Control risk factors especially BP control
61
Investigations Screening for AAA
: Men > 65 can ask for one off abdominal US to assess AA size Men/women AAA size: - < 3cm= normal - 3-4.4cm= small- yearly scan (usually grow < 0.5cm/year) - 4.5-5.4cm= medium- 3 monthly scan - > 5.5cm or growth > 1 cm/yr or symptomatic need referral within 2 weeks for elective surgery (risk rupture > risk of surgery)
62
Investigation in AAA rupture Gold standard?
Rupture: Bedside focused USS can identify ruptured AAA in minutes CT angiography is gold standard Group and save and crossmatch 6 units Routine bloods including FBC, UE, LFT, coagulation
63
Diagnosis of AAA
Based on imaging findings and clinical presentation. Emergency diagnosis and management of ruptured aneurysms is crucial.
64
Symptoms and findings in AAA
History May be asympomtomatic until rupture- hence screening programme Abdominal pain radiating to back which may be sudden and severe if ruptured Examination Findings Palpable pulsatile mass in the abdomen Auscultation may reveal bruits over the aneurysm Signs of shock if ruptured ( hypotensive, tachycardic, cold and clammy, reduced GCS)
65
Epedemiology and risk factors of AAA
Epidemiology More prevalent in older adults, especially males Risk factors Smoking Hypertension Connective tissue disorders i.e. Marfan syndrome, Ehler's Danlos Family history aneurysms
66
Definition and pathophysiology
Definition Abnormal localised dilatation of vessel of over 50% of normal diameter Aortic aneurysm = 3cm or above Pathophysiology A weakening of the aortic wall leads to bulging or dilation, predisposing to rupture All three layers of vessel involved (less = pseudo-aneurysm) Commonly involves the abdominal aorta (AAA) - most commonly infrarenal
67
Coarctation of the Aorta Pathology: congenital narrowing of part of the aorta
Associated conditions Turners Syndrome Bicuspid aortic valve Clinical features Infancy – features of heart failure, failure to thrive Adulthood - uncontrolled hypertension Examination findings Radio-femoral delay A systolic murmur - left infraclavicular area and may be loudest below the left scapulae Apical click may be heard Investigations CXR: Notching of the inferior border of the ribs - Roesler sign
68
Aortic dissection risk factors and cf
Aortic Dissection Pathology: tear within the tunica intima allows blood to flow between the layers of the aorta Risk factors Hypertension Marfans, Ehlers Danlos Turners syndrome / Noonan syndrome Clinical Features “Tearing” chest pain radiating into the back, between the scapulae Aortic regurgitation - early diastolic murmur
69
70
Diagnosis and management of aortic dissection
Diagnosis: CT angiogram Stanford Classification Type A – Dissection of the ascending aorta – most common Type B – Dissection of the descending aorta Management Type A Surgical management Permissive hypotension – target 100-120mmHg systolic BP (labetalol if req.) Type B Medical management – no surgery! Labetalol given to reduce BP which reduces progression of dissection
71
Arterial Ulcers Key learning
Epidemiology: Less common than venous ulcers; often in elderly with cardiovascular disease or diabetes. Causes: Primarily peripheral arterial disease (PAD); also embolism, thrombosis, or vasculitis. Clinical Features: Pain at rest/elevation; located on pressure points; deep, 'punched out' appearance. Examination Findings: Cool, pale skin; diminished pulses; delayed capillary refill; necrotic ulcer base. Investigations: ABPI < 0.8 indicates arterial insufficiency; < 0.5 suggests PAD-related ulceration. Utilise Doppler ultrasound and arterial duplex imaging. Management: Step-wise approach of lifestyle changes, pharmacological management (antiplatelets, statins) and surgical management (revascularisation/ wound debridement).
72
Pathophysiology Epidemiology Causes Clinical features of Arterial ulcer
Pathophysiology Result from inadequate blood flow to the extremities, leading to tissue ischemia and subsequent ulceration Epidemiology Less common than venous ulcers Elderly individuals with underlying cardiovascular disease or diabetes. Causes Peripheral arterial disease (PAD) Other causes include embolism, thrombosis, or vasculitis. Clinical Features Painful, especially at rest or with elevation Tend to be located on pressure points including tips of toes, heels, or metatarsal heads
73
Examination Findings of arterial ulcers
Arterial ulcers classically appear deep and 'punched out' Cool, pale, or cyanotic skin Diminished or absent pulses Delayed capillary refill The ulcer base may appear necrotic, with surrounding tissue exhibiting signs of ischemia.
74
Investigation of arterial ulcer
Investigations Ankle-brachial pressure index (ABPI) measurement ABPI < 0.8= arterial insufficiency < 0.5 is suggestive of PAD-related ulceration. Doppler ultrasound, and arterial duplex imaging To assess arterial blood flow and identify any stenosis or occlusion.
75
Management and complication of arterial ulcer
Management Treatment aims to improve arterial perfusion 1) Lifestyle modifications (stop smoking, weight loss, exercise) 2) Medication (antiplatelets, statins) 3) Revascularization procedures (angioplasty, bypass surgery), wound debridement, and wound care. Complications Delayed healing Infection- can progress to osteomyelitis Progression to gangrene
76
Aspect pathophysiology Venous Ulcers Arterial Ulcers Diabetic Ulcers
Aspect Venous Ulcers Arterial Ulcers Diabetic Ulcers Pathophysiology Chronic venous insufficiency, leading to impaired venous return, venous hypertension, and tissue hypoxia Peripheral arterial disease (PAD), resulting in inadequate blood flow, tissue ischemia, and subsequent ulceration Neuropathy, microvascular disease, and impaired wound healing due to diabetes-related metabolic changes
77
Aspect Venous Ulcers Arterial Ulcers Diabetic Ulcers
Epidemiology Common, particularly in older adults and those with a history of deep vein thrombosis (DVT) or varicose veins Less common but often seen in elderly individuals with underlying cardiovascular disease or diabetes Common in diabetic patients, especially those with poor glycemic control or long-standing disease
78
Aspect Venous Ulcers Arterial Ulcers Diabetic Ulcers
79
Aspect location of ulcer Venous Ulcers Arterial Ulcers Diabetic Ulcers
Location of Ulcers Typically located on the lower legs, near the medial malleolus Commonly found on the toes, heels, or lateral ankle pressure points Predominantly affect the feet, particularly over pressure points such as the plantar surface
80
Aspect history Venous Ulcers Arterial Ulcers Diabetic Ulcers
History - Painful - Worse on standing - Painful - Worse at night when legs elevated - Often painless - Report abnormal sensation
81
Aspect examination findings Venous Ulcers Arterial Ulcers Diabetic Ulcers
Examination Findings - Large shallow irregular ulcer - Granulating base with irregular edges - Associated oedema, hyperpigmentation, venous eczema, lipodermatosclerosis - Warm skin, normal pulses - Ulcers small, sharply defined - Deep and ‘punched out’ with necrotic base and surrounding ischemic tissue - Cool, pale, or cyanotic skin - Diminished or absent pulses, delayed capillary refill - Variable size/depth - Calluses - Signs of peripheral neuropathy -May have signs of infection - Warm skin - Normal pulses if no co-existing ischaemia
82
Aspect investigation Venous Ulcers Arterial Ulcers Diabetic Ulcers
Investigations - Doppler ultrasound to assess venous reflux, venous duplex imaging, - Ankle-brachial pressure index (ABPI) typically > 0.8 - Doppler ultrasound/angiography - ABPI typically < 0.8 - Assessment of glycemic control (HbA1c) - Screening for neuropathy -ABPI > 0.8 -XR - exclude osteomyelitis
83
Aspect Venous Ulcers Arterial Ulcers Diabetic Ulcers Management
Management - Compression bandaging if excluded arterial insufficiency - Leg elevation - Wound care - Smoking cessation - Wound care - Antiplatelet therapy - Revascularization procedures (angioplasty, bypass surgery) - Optimize glycemic control - Wound debridement - - Offloading pressure areas - Wound care - Screening and management of diabetic complication
84
Aspect complication Venous Ulcers Arterial Ulcers Diabetic Ulcers
Complications Delayed healing, recurrent ulcers, cellulitis, venous stasis dermatitis, venous eczema Delayed healing, infection, gangrene, progression to limb ischemia, amputation Delayed healing, infection, progression to osteomyelitis, amputation, increased risk of recurrent ulcers
85
Management of unstable bradycardia
If there are any of the above life-threatening features treat as follows: Give atropine 500mcg IV Repeat step 1 every 3-5 minutes (up to total of 3mg atropine) If ineffective consider (a) transcutaneous pacing OR (b) second line medications: Isoprenaline Adrenaline Aminophyline – if bradycardia is secondary to spinal cord injury/recent inferior MI. Glucagon – if bradycardia is caused by beta-blocker or CCB If this fails consider transvenous cardiac pacing
86
87
88
Atrioventricular Block
1st degree block PR > 200ms 2nd degree HB Mobitz I (Wenkebach) – progressive PR prolongation until dropped QRS complex Mobitz II – Prolonged PR interval is constant with dropped QRS complexes More serious – higher risk of progressing to complete HB
89
3rd degree heart block
3rd degree HB Complete dissociation between P waves and QRS complexes Examination findings: Cannon A waves (irregular) Wide pulse pressure Variable S1 intensity
90
Bradyarrhythmia guidelines https://www.resus.org.uk/sites/default/files/2020-05/G2015_Adult_bradycardia.pdf Assessment
Step 1: Identify adverse features Shock (e.g. Systolic < 90mmHg) Syncope Features of myocardial ischaemia – chest pain Symptoms of severe heart failure – hypoxia, crepitations etc. Risk factors for asystole including: Recent asystole Mobitz type 2 block Complete heart block with QRS > 120 Ventricular pause > 3 seconds
91
92
Cardiac arrest Key learning
Key learning: See summary 2021 ALS guidelines below CPR 30 chest compressions : 2 breaths Assess rhythm: Shockable= VF (see ECG below)/pulseless VT If shockable give one shock, resume CPR and repeat rhythm check in 2 minutes, continue giving shocks if in shockable rhythm If given 3 shocks- give amiodarone Non-shockable= Pulseless electrical activity (PEA)/ asystole In both shockable and non-shockable- given adrenaline every 3-5 minutes
93
4H and 4T
Identify reversible causes (4Hs and 4Ts): Hypoxia Hypovolaemia Hypo/hyperthermia Hypo/hyperkalaemia/other metabolic abnormalities Thrombosis- coronary or pulmonary (PE) Tension pneumothorax Tamponade (cardiac) Toxins (review drug chart/overdose history
94
Cardiac tamponade Pathology
Cardiac Tamponade Pathology Causes include: Trauma, MI, Cardiac surgery, malignancy Accumulation of fluid within the pericardium. Consequently, intrapericardial pressures > diastolic pressures This results in impaired diastolic filling of the heart –> reduced cardiac output.
95
96
Cardiac tamponade Cf Investigation Mng
Clinical features Shortness of breath Tachycardia Becks Triad – Hypotension, muffled heart sounds, raised JVP JVP – absent Y descent (due to limited right ventricular filling) Pulsus paradoxus Investigations ECG findings: Electrical alterans – alternation of QRS amplitude between each beat Management Urgent pericardiocentesis
97
Takotsubo cardiomyopathy
Pathology: The ballooning of the myocardial apex due to severe hypokinesia, not caused by ischaemia. Causes: Severe emotional stress – bereavement, heartbreak Features: Chest pain, ST elevation but normal coronary arteries on angiogram Management: Supportive
98
Restrictive cardiomyopathy
Pathology: Reduced ventricular compliance leads to diastolic dysfunction with impaired ventricular filling. Causes Amyloidosis – AL (myeloma) Sarcoidosis, Haemochromatosis, Scleroderma ECG changes: Low voltage ECG complexes, bundle branch block
99
Dilated cardiomyopathy The commonest form of cardiomyopathy, accounting for 90% of cases. Pathology: Dilation of all four cardiac chambers leads to systolic dysfunction
Causes Drugs: Alcohol, chemotherapy – esp. doxorubicin Myocarditis: (Coxsackie B) Peripartum, Duchenne MD CXR changes: “Balloon heart” On examination: 3rd heart sound
100
Hypertrophic cardiomyopathy (HOCM) The commonest cause of sudden cardiac death.
Inheritance: autosomal dominant Pathology: Mutation in genes encoding the B-myosin heavy chain or myosin binding protein C lead to left ventricular hypertrophy (LVH) and remodelling Clinical Features: Presentation: Syncope, angina, shortness of breath on exertion, SCD in a young patient Ejection systolic murmur due to ventricular outflow obstruction from LVH Jerky pulse, double apical pulse S4 heart sound Associations: Friedreich's ataxia and WPW Echocardiogram: Mitral regurgitation (MR) + systolic anterior motion (SAM) of the anterior valve leaflet with asymmetrical hypertrophy (ASH). Mnemonic: MR SAM ASH ECG changes: Deep Q waves, Progressive T wave inversion, LAD and LVH Management: ICD, dual chamber PM, amiodarone, beta blockers/RLCCBs
101
Hypertrophic cardiomyopathy (HOCM)
Associations: Friedreich's ataxia and WPW Echocardiogram: Mitral regurgitation (MR) + systolic anterior motion (SAM) of the anterior valve leaflet with asymmetrical hypertrophy (ASH). Mnemonic: MR SAM ASH ECG changes: Deep Q waves, Progressive T wave inversion, LAD and LVH Management: ICD, dual chamber PM, amiodarone, beta blockers/RLCCBs
102
Pulses
Anacrotic pulse - slow-rising Aortic stenosis Collapsing pulse Aortic regurgitation, PDA Pulsus alterans - alternating strong then weak pulses Severe left ventricular failure (LVF) Jerky pulse HOCM Pulsus paradoxus - pulse becomes softer during inspiration due to a drop in SBP Cardiac tamponade Severe asthma attack
103
Murmurs Ejection systolic murmur
Aortic / pulmonary stenosis HOCM Tetralogy of fallot ASD
104
Pansystolic murmur
Mitral/tricuspid regurgitation – “high pitched/blowing” Ventricular septal defect – “Harsh” sound
105
Early diastolic murmur
Aortic regurgitation Pulmonary regurgitation
106
Mid-to-late diastolic murmur
“Rumbling MDM” – mitral stenosis Tricuspid stenosis
107
Continuous/machine like murmur
PDA, associated with left subclavian thrill
108
Manoeuvres/radiation:
Aortic– radiates into carotids Mitral – radiates into the axilla Left sided murmurs are heard with increased intensity on expiration (lEft = Expiration) – aortic / mitral Right sided murmurs are heard with increased intensity on inspiration (rIght – Inspiration)
109
Heart sounds S1: Caused by the closure of the mitral / tricuspid valves
Quiet S1: Mitral regurgitation Loud S1: Mitral stenosis
110
S2: Caused by the closure of the aortic (A2) & pulmonary valves (P2)
Quiet S2: Aortic stenosis Loud P2: Pulmonary hypertension
111
Split S2: When A2 and P2 can be heard distinctly
Fixed split: ASD
112
S3 (ventricular gallop): Due to increased left ventricular compliance
Causes of S3: Dilated cardiomyopathy, constrictive pericarditis, HF
113
S4 (atrial gallop): Due to active filling of the left ventricle on contraction of the atria (coincides with the P wave)
Causes: Diastolic heart failure, HOCM
114
Manoeuvres/radiation:
Aortic– radiates into carotids Mitral – radiates into the axilla Left sided murmurs are heard with increased intensity on expiration (lEft = Expiration) – aortic / mitral Right sided murmurs are heard with increased intensity on inspiration (rIght – Inspiration)
115
Acyanotic CHD Ventricular Septal Defect
Ventricular Septal Defect Ventricular septal defect (VSD) is a congenital heart defect with an opening in the interventricular septum. This allows blood flow between the left and right ventricles, resulting in mixing of oxygen-rich blood from the left ventricle with deoxygenated blood in the right ventricle. The severity of symptoms depends on the size and location of the VSD. Causes Chromosomal disorders: Downs, Patau's syndrome Post-MI
116
Vsd Acyanotic heart disease
Clinical features Failure to thrive Heart failure Hepatomegaly Tachypnoea Examination findings: Harsh pansystolic murmur loudest at the lower left sternal edge Complications
117
Vsd Complication
Harsh pansystolic murmur loudest at the lower left sternal edge Complications Eisenmenger’s syndrome The initial left to right shunt causes pulmonary hypertension Pulmonary HTN causes RVH with increased right heart pressures At a certain point the pressure generated by the right ventricle > left ventricle - the shunt reverses leading to a RIGHT TO LEFT shunt Signs: Cyanosis, clubbing Requires surgical management
118
Atrial Septal Defects
Commonly identified in adulthood with Shortness of breath, esp. on exertion PHTN and RHF Arrhythmias - AF Stroke following DVT - classic exam q - the clot is able to pass through defect from RA to LA and into systemic circulation
119
ASD
Classification Ostium Primum ASD Defect of the atrial septum near the AV valve Commonly associated with Down’s syndrome Ostium Secundum ASD Defects of the superior atrial septum MOST COMMON form of ASD Examination findings Ejection systolic murmur Fixed splitting of S2 Holt-Oram syndrome: ASD + triphalangeal thumbs
120
Patent Ductus Arteriosus Pathophysiology
Connection between the pulmonary trunk and the descending aorta. Usually closes when the neonate takes their first breath - increased pulmonary blood flow which results in prostaglandin clearance Incomplete closure causes PDA Risk factors: Prematurity, maternal rubella Examination findings Continuous 'machinery-like' murmur Left subclavicular thrill Bounding, collapsing pulse
121
PDA Mng
Management INDOMETHACIN or ibuprofen - inhibit production of prostaglandins
122
Patent Foramen Ovale Connects the atria - usually closes 6 months to 1 year after birth.
Complications: The connection between the right and left heart mean that deep vein thrombosis / PEs can travel to the arterial circulation and cause stroke
123
Cyanotic vs Acyanotic congenital heart disease
Congenital heart disease (CHD) can be classified as cyanotic or acyanotic. Cyanotic CHD occurs when deoxygenated blood passes into the systemic circulation. This occurs in the context of a right-to-left shunt, where deoxygenated blood returns from the body to the right heart, then passes directly into the left heart, bypassing the pulmonary circulation/lungs, and therefore not having been re-oxygenated. Deoxygenated blood is then pumped from the left heart around the body, with resultant hypoxia and cyanosis.
124
Cyanotic CHDs include the 3 T’s Tetralogy of Fallot (TOF) – the most common cyanotic CHD (presents after approx. 1 month) Transposition of the Great Arteries (TGA) – most common cause of cyanosis at birth Tricuspid atresia Acyanotic CHDs include Ventricular septal defect – most common Atrial septal defect Coarctation of the aorta Patent ductus arteriosus
Cyanotic CHDs include the 3 T’s Tetralogy of Fallot (TOF) – the most common cyanotic CHD (presents after approx. 1 month) Transposition of the Great Arteries (TGA) – most common cause of cyanosis at birth Tricuspid atresia Acyanotic CHDs include Ventricular septal defect – most common Atrial septal defect Coarctation of the aorta Patent ductus arteriosus
125
Cyanotic CHDs include the 3 T’s Tetralogy of Fallot (TOF) – the most common cyanotic CHD (presents after approx. 1 month) Transposition of the Great Arteries (TGA) – most common cause of cyanosis at birth Tricuspid atresia Acyanotic CHDs include Ventricular septal defect – most common Atrial septal defect Coarctation of the aorta Patent ductus arteriosus
Cyanotic CHDs include the 3 T’s Tetralogy of Fallot (TOF) – the most common cyanotic CHD (presents after approx. 1 month) Transposition of the Great Arteries (TGA) – most common cause of cyanosis at birth Tricuspid atresia Acyanotic CHDs include Ventricular septal defect – most common Atrial septal defect Coarctation of the aorta Patent ductus arteriosus
126
127
128
129
130
Cyanotic CHD Tetralogy of Fallot TOF is the most common cause of cyanotic congenital heart disease
. Defects 1.Ventricular septal defect 2.Pulmonary stenosis causing right ventricular outflow obstruction 3.Overriding aorta 4.Right ventricular hypertrophy Right heart pressure > left heart pressure due to the presence of pulmonary stenosis and right ventricular outflow obstruction The VSD allows the passage of blood from the right heart to the left, resulting in a RIGHT TO LEFT SHUNT, and cyanosis as described above.
131
Tof Mng Investigation
Examination findings Ejection systolic murmur loudest in the pulmonary area, on inspiration – pulmonary stenosis Clubbing Investigations CXR - classically shows a ‘boot shaped’ heart due to RVH Echocardiogram - the investigation of choice Management Prostaglandin infusion in neonates - maintains the ductus arteriosus, which allows blood to flow from the aorta into the pulmonary arteries Definitive management - Total surgical repair (open heart surgery) Tet spells can be managed with beta blockers, morphine etc.
132
Cf of TOF
Clinical features If not diagnosed antenatally or at newborn check, may present 1-2 months postpartum with Cyanosis, dyspnoea Failure to thrive, poor feeding and poor weight gain Tet spells - acute worsening of cyanosis often precipitated by exertion/crying Tearful, irritable, agitated Dyspnoeic Squat to improve venous return
133
Tof
Right heart pressure > left heart pressure due to the presence of pulmonary stenosis and right ventricular outflow obstruction The VSD allows the passage of blood from the right heart to the left, resulting in a RIGHT TO LEFT SHUNT, and cyanosis as described above.
134
Yea
135
Transposition of the Great Arteries Pathology: Transposition of the aorta and the pulmonary artery results in deoxygenated blood circulating around the body. Risk factors: MATERNAL DIABETES
CXR: "egg on it's side" appearance Management PE1 (alprostadil) to maintain patency of the ductus arteriosus and allow mixing of oxygenated and deoxygenated blood Surgical management is required
136
Tricuspid Atresia Tricuspid atresia is a congenital heart disease marked by the absence of the tricuspid valve, preventing blood flow from the right atrium to the right ventricle.
Defects Absent tricuspid valve: No right atrium to right ventricle connection. Hypoplastic right ventricle: Underdeveloped right ventricle. Atrial septal defect (ASD): Allows blood to flow from right atrium to left atrium. Ventricular septal defect (VSD): Permits blood flow from the left ventricle to the pulmonary artery. Pulmonary stenosis or atresia: Often present, restricting pulmonary blood flow. Left ventricular hypertrophy: Increased workload on the left ventricle.
137
Examination findings and management of tricuspid atresia
Examination Findings Cyanosis Tachypnoea Murmurs: Holosystolic (VSD) or ejection systolic (pulmonary stenosis) Clubbing (in chronic cases) Management Prostaglandin infusion: Maintains ductal patency for pulmonary blood flow. Surgical intervention: including Blalock-Taussig shunt, Glenn procedure, Fontan procedure.
138
Tricuspid atresia
In tricuspid atresia, blood returns to the heart through the superior and inferior vena cava into the right atrium but cannot pass into the right ventricle due to the absence of the tricuspid valve, resulting in a hypoplastic right ventricle. A right-to-left shunt at the atrial level allows blood to mix in the left atrium, leading to variable oxygenation levels in the blood reaching the left ventricle and the systemic circulation.
139
Tricuspid atresia
Clinical Features Presentation typically within the first few days to weeks: Cyanosis Dyspnoea Failure to thrive Fatigue
140
Coronary arterial territories See ACS notes for STEMI ECGs
Anteroseptal: Leads V1-V4 – supplied by the LAD Lateral – Leads 1, aVL, V5-6 – suppled by the left circumflex Inferior – Leads II, III, aVF – supplied by the RCA Note: ST depression in V1-3 can represent a posterior STEMI – confirm with V7-V9 lead placement (supplied by left circumflex)
141
Pericarditis
Global PR depression (commonest) Saddle shaped ST elevation
142
Brugada Syndrome
Convex ST elevation followed by T wave inversion in V1-V3 Incomplete RBBB
143
Arrhythmogenic Right Ventricular Cardiomyopathy
Right ventricular hypertrophy – RAD, dominant R in V1 Right ventricular strain – T wave inversion in V1-V3 Epsilon waves – a small notch which follows QRS complex
144
Cardiac Tamponade
Small QRS complexes Electrical alterans
145
Digoxin toxicity
Prolonged PR Down sloping ST depression T wave inversion Short QT Bradycardia Tip: Digoxin toxicity ECGs are said to have a ‘reverse Nike tick’ appearance with the down sloping of the ST and the T wave inversion.
146
Hypothermia
Prolonged PR interval Long QTc J waves (Osborn waves) Bradycardic Tip: ECG slows down/gets frozen – slow rate, long pr, long qt Hypothermia including Osborn (J) wave Figure 109: Hypothermia including Osborn (J) wave.
147
Characteristic ECG Patterns Wolff Parkinson White
Short PR interval Broad QRS complexes Delta wave - Slurred upstroke to the QRS Wolff Parkinson White Figure 110: Wolff Parkinson White. User Ksheka on en.wikipedia, Wolff-Parkinson-White syndrome 12 lead EKG, CC BY-SA 3.0
148
Hypercalcaemia
Short QTc
149
Hypocalcaemia
Long QTc
150
Hyperkalaemia
Flattened P waves Prolonged PR interval Tall Tented T waves Bradycardia Broad QRS Severe hyperkalaemia – sinusoidal pattern
151
Electrolyte Derangement Hypokalaemia
U waves Flat/inverted T waves Prolongation of PR Long QTc ST depression Memory aid: U have no Pot and no T, but a long PR, a long QT and a depressed ST
152
153
Heart failure describes an abnormality in cardiac structure and/or function resulting in inadequate cardiac pressures or output, manifested by symptoms & signs such as dyspnoea, fatigue and peripheral oedema.
Aetiology Coronary artery disease/ IHD is the most common cause Other causes include: Hypertension, Valvular heart disease (VHD), cardiomyopathy, CHD, arrhythmias (AF) etc.
154
Classification NICE define HF according to the left ventricular function:
Heart failure with reduced ejection fraction (HF-REF) if the LVEF is < 40% HF with mildly reduced EF (HFmrED) - EF 41-49% Heart failure with preserved ejection fraction (HF-PEF) Approximately 50% of patients Symptoms/signs of HF/ abnormalities in cardiac structure/pressures with LVEF > 50%
155
The New York Heart Association (NYHA) Classification can be used to categorise the severity of HF according to the limitation of ADLs due to symptoms (SOB/angina)
Class 1: No limitation Class 2: Slight limitation of ordinary activity Class 3: Significant limitation. Only comfortable at rest. Class 4: Severe limitations. Symptoms present at rest. Often bedbound.
156
Clinical features Symptoms Heart failure
Symptoms SOB - worse on exertion PND, orthopnoea Oedema - ankles, weight gain, abdominal distension Tired all the time (TATT) Elevated JVP
157
Investigations of heart failure
Step 1: Measure NT-Pro BNP NT-Pro BNP > 2000ng/L High - Specialist assessment and echocardiogram within 2 weeks NT-Pro BNP 400-2000ng/L Raised - Specialist assessment and echocardiogram within 6 weeks NT-Pro BNP < 400ng/L Normal – HF is unlikely Note: NT-Pro BNP may be falsely lowered by.. ACEi/ARBs/beta-blockers and aldosterone antagonists Obesity (BMI > 35) African-Carribean ethnicity Step 2: Echocardiogram
158
Other investigations: CXR
A: alveolar oedema (perihilar/bat-wing opacification) B: Kerley B lines (interstitial oedema) C: cardiomegaly (cardiothoracic ratio >50% on PA film) D: dilated upper lobe vessels E: effusions (pleural effusions – blunted costophrenic angles with meniscus sign)
159
NICE Guidelines – Management of Heart Failure with reduced Ejection Fraction (HFrEF) Step 1
Prescribe a combination of both ACE inhibitor AND a B-blocker Do not offer ACEi if suspected significant valve disease Switch to an ARB if unable to tolerate ACEi (e.g. due to cough) Step 2 If patient remains symptomatic - offer an MRA - e.g. spironolactone, eplerenone
160
Step 3 - Specialist management If still symptomatic despite optimal treatment, seek specialist advice and consider:
1. Ivabradine – consider if ejection fraction (EF) < 35% AND in sinus rhythm with HR > 75bpm 2. Sacubitril-valsartan – consider if EF < 35% Stop the ACEi/ARB prescribed initially 3. SGLT-2 inhibitor - dapagliflozin, empagliflozin 4. Digoxin – consider in sinus or especially if co-existent AF 5. Hydralazine + Nitrate - consider especially if patient is of African-Caribbean family origin 6. Cardiac resynchronisation therapy (CRT) - consider for symptomatic benefit, especially if the patient has HF with a wide QRS consider biventricular pacing Improves symptoms but not mortality
161
Heart failure with preserved ejection fraction (HFpEF)
The mainstay of management of HFpEF is with diuretics for symptomatic relief. There is no proven survival benefit associated with ACEi/B-blockers SGLT-2 inhibitors (dapagliflozin, empagliflozin) are now recommended by NICE
162
Other treatments for Heart Failure
1. Symptomatic relief - Loop diuretics Furosemide, bumetanide, torasemide - symptomatic relief, no impact on mortality 2. Vaccinations Annual influenza vaccine One off pneumococcal vaccine Antiplatelets- if atherosclerotic arterial disease 3. Lipid modification - Statin 4. Cautions - avoid rate limiting CCBs (verapamil/diltiazem) in patients with heart failure References & Further Reading: National Institute for Health and Care Excellence [NICE] (2022). Heart Failure - Chronic. https://cks.nice.org.uk/topics/heart-failure-chronic/ - Revised October 2023
163
Hypertension Diagnosis and Classification of Hypertension
If clinic BP > 140/90 (but < 180/120) – perform ABPM or HBPM to confirm diagnosis If > 180/120 see below Stage 1 Hypertension Clinic BP > 140/90 Ambulatory blood pressure monitor (ABPM) > 135/85 Stage 2 Hypertension Clinic BP > 160/100 Ambulatory blood pressure monitor (ABPM) > 150/95 Severe hypertension Blood Pressure > 180/120 Accelerated hypertension: Stage 3 + Retinal haemorrhages/papilloedema - Admit
164
Initial management of Severe Hypertension (BP > 180/120)
Admit if accelerated hypertension as above OR if there are features of a hypertensive emergency (chest pain, HF, acute renal failure). Consider investigating for secondary causes of hypertension (phaeochromocytoma etc.) If no indication for admission, perform urgent investigations to investigate for end organ damage: Bloods / ACR / ECG If there is evidence of end organ damage, initiate treatment immediately (before ABPM). If not, repeat clinic BP in 7 days
165
Management of Hypertension If referral is not required Investigate for EOD Calculate QRISK Lifestyle advice Consider antihypertensive drug treatment as below..
For Stage 2 HTN (clinic 160/100 or ABPM > 150/95) Offer antihypertensive drug treatment For Stage 1 HTN (clinic 140/90 or ABOM 135/85) If < 80 years - start antihypertensive drug treatment if any one of the following: Evidence of EOD Cardiovascular disease or QRISK > 10% Comorbidities - CKD or diabetes “consider” antihypertensive drugs if < 60 yrs and QRISK < 10% “consider” antihypertensive drugs if If > 80 years and clinic BP > 150/90
166
Blood Pressure – Targets
Age < 80 – aim for… Clinic BP < 140/90 ABPM < 135/85 Age > 80 - add 10 to systolic - aim for… Clinic BP < 150/90 ABPM < 145/85 In patients with CKD and diabetes or if urine albumin to creatinine ratio (ACR) >70 mg/mmol) A blood pressure below 130/80 mmHg is advised i
167
Pharmacological management – Stepwise choice of antihypertensives Useful Resource: NICE - visual summary - Hypertension in Adults: Diagnosis and Treatment https://www.nice.org.uk/guidance/ng136/resources/visual-summary-pdf-6899919517
168
Age < 55 years OR diagnosis of diabetes mellitus (irrespective of age/ethnicity)
STEP 1: ACE inhibitor Used in diabetics regardless of age due to renoprotection benefits Trial ARB if the ACEi not tolerated (e.g. due to cough) Step 2: Continue ACEi/ARB Add either a CCB OR a thiazide like diuretic (TLD) Step 3: ACEi + CCB + TLD Step 4: Resistant hypertension - See below
169
Age > 55 years OR African-Caribbean (any age), and NOT diabetic
Step 1: CCB Step 2: Continue CCB Add either a ACEi/ARB OR a thiazide like diuretic (TLD) Step 3: CCB + ACEi + TLD Step 4: Resistant hypertension - See below
170
Step 4 – treatment of ‘resistant hypertension
’ If the potassium is < 4.5 – commence low dose spironolactone Remember - side effect of mineralocorticoid receptor antagonists - hyperkalaemia If the potassium is > 4.5 – commence alpha or beta blocker
171
Step 5 – If still hypertensive on 4 drugs, refer to specialist
Nb. Thiazide-like diuretics Indapamide is the TLD recommended by NICE Alternatives include chlortalidone, metolazone
172
References & Further Reading: National Institute for Health and Care Excellence [NICE] (2019). Hypertension in adults: diagnosis and management [NG136]. https://www.nice.org.uk/guidan...
173
Infective endocarditis
Infective endocarditis describes inflammation of the endocardium, most commonly of infectious aetiology. Causative organisms Staphylococcus Aureus The most common organism Staphylococcus Epidermis The most common post-valve surgery (for the first 2 months post op) Can also colonise indwelling lines Streptococcus Viridans Include Streptococcus Mitis and Streptococcus Sanguinis Common following dental work or in patients with poor dental hygiene Streptococcus Bovis Subtypes include Streptococcus Gallolyticus Most common in patients with colorectal cancer Therefore, consider a colonoscopy if gallolyticus positive Other ‘culture negative’ causes of infective endocarditis include: 1.The B’s: coxiella Burnetti, Brucella, Bartonella 2. HACEK: Haemophilus, Actinobacillus, Cardiobacterium, Eikenella, Kingella
174
Diagnosis of Infective Endocarditis Duke Criteria
The modified Duke criteria can be used to aid the diagnosis of infective endocarditis. Pathological features: Positive histopathology from cardiac surgery/autopsy Major features: Positive blood cultures or serology Evidence of endocardial involvement – new valvular regurgitation / positive echocardiogram
175
Minor features: IE
History of cardiovascular conditions or IVDU – predisposing factors Pyrexia > 38 degrees Vascular phenomena - septic emboli, Janeway lesions Immunological phenomena – Osler nodes, Roth spots, Glomerulonephritis
176
Examination findings I E
Janeway lesions - irregular, nontender haemorrhagic macules, present on the palms of hands and soles of feet. Osler nodes - tender, red-purple lesions, located most commonly in the pulp of the fingers/toes Roth spots - white-centred retinal haemorrhages
177
Investigations IE
TTE is often used as the initial investigation of choice, due to its less invasive nature However, TOE is more sensitive and specific and therefore is of value if High clinical suspicion remains despite a negative TTE Results of the TTE are equivocal Prosthetic valve Positive TTE - but suspected complication/virulent organism
178
179
Management of Infective Endocarditis
❤️Prophylaxis NOT recommend for common procedures e.g. dental work / GI surgery ❤️Blind therapy Native valve: Amoxicillin (+ consider gentamicin) Prosthetic valve: Vancomycin + gentamicin + rifampicin ❤️Staphylococci Native valve: Flucloxacillin Prosthetic valve: Flucloxacillin + gentamicin + rifampicin ❤️Streptococci Benzylpenicillin is 1st line
180
Indications for surgery in IE
Severe valvular incompetence Cardiac failure which is refractory to medical management/diuretics etc. Presence of an aortic abscess Suggested by prolongation of the PR interval on ECG
181
182
Catecholaminergic polymorphic ventricular tachycardia (CPVT)
Inheritance: Autosomal dominant Pathology: Mutation in ryanodine receptor (RYR2) in the myocardial sarcoplasmic reticulum Presentation: Emotional stimuli/exertion causes PVT presenting with syncope or SCD Management: Beta blockers/ ICD
183
Long QT Syndrome
Inheritance: Autosomal dominant Subtypes: LQT1 – typical presentation = exertional syncope (e.g. whilst swimming) LQT2 – present with syncope following auditory stimuli/ emotional stress Pathology: Defect of the alpha subunit of the slow cardiac potassium channel. Management: ICD, avoid drugs which prolong the QTC.
184
Brugada Syndrome Inheritance: Autosomal dominant Presentation: Sudden cardiac death (SCD) - mean age of death is 41 yrs More common in Asian ethnicities, especially SE Asia including the Phillipines
Inheritance: Autosomal dominant Presentation: Sudden cardiac death (SCD) - mean age of death is 41 yrs More common in Asian ethnicities, especially SE Asia including the Phillipines Pathology: SCN5a gene mutation (Na+ channel in myocardium) 50% of cases are inherted, in an autosomal dominant fashion There may be no FHx in the other 50%, which result from a new spontaneous mutation ECG changes: Convex ST elevation > 2mm in more than 1 of V1, V2 or V3 followed by negative T wave Partial RBBB Investigation: Flecainide or Ajmaline provocation test - ECG changes become more obvious Management: ICD
185
Arrhythmogenic right ventricular cardiomyopathy (ARVC)
The second most common cause of sudden cardiac death. Inheritance: Autosomal dominant Pathology: Abnormal cardiac desmosomes. Right ventricular myocardium is replaced by fibrous and fatty tissue ECG changes: T wave inversion in V1, V2, V3 Epsilon wave (a terminal notch seen after the QRS complex) Management: Sotalol, ICD, Catheter ablation to reduce risk of VT Naxos disease = ARVC + palmoplantar keratosis + woolly hair
186
Inherited Cardiac Disorders Hypertrophic cardiomyopathy (HOCM)
) The commonest cause of sudden cardiac death. Inheritance: autosomal dominant Pathology: Mutation in genes encoding the B-myosin heavy chain or myosin binding protein C lead to left ventricular hypertrophy (LVH) and remodelling Clinical Features: Presentation: Syncope, angina, shortness of breath on exertion, SCD in a young patient Ejection systolic murmur due to ventricular outflow obstruction from LVH Jerky pulse, double apical pulse S4 heart sound
187
Hypertrophic cardiomyopathy (HOCM)
Associations: Friedreich's ataxia and WPW Echocardiogram: Mitral regurgitation (MR) + systolic anterior motion (SAM) of the anterior valve leaflet with asymmetrical hypertrophy (ASH). Mnemonic: MR SAM ASH ECG changes: Deep Q waves, Progressive T wave inversion, LAD and LVH Management: ICD, dual chamber PM, amiodarone, beta blockers/RLCCBs
188
Constrictive Pericarditis Examination findings: Loud S3 Pericardial knock JVP Kussmaul’s sign positive - a paradoxical rise JVP on inspiration Investigations CXR: Pericardial calcification Figure 194: Constrictive pericarditis with extensive calcifications. Pericarditis constrictiva mit massiven Verkalkungen.
Pathophysiology The pericardium becomes thickened and fibrotic forming a ‘non-compliant shell’ which impairs filling and causes diastolic dysfunction Causes The same causes as listed above for pericarditis, especially TB Post cardiac surgery, radiotherapy Clinical Features Symptoms - Shortness of breath
189
Pericarditis Inflammation of the pericardium, the protective outer lining of the heart
. Causes Viral – Coxsackie B, influenza, covid-19 Autoimmune - Rheumatoid arthritis Tuberculosis Uraemia / renal failure Post MI pericarditis Dressler’s syndrome Clinical features Pleuritic chest pain, positional – relieved leaning forwards, worse when lying down Flu-like symptoms Fever
190
Pericarditis Mng
Examination findings Pericardial rub over the left sternal border - a ‘grating’ like sound which occurs as layers of inflamed pericardium slide over one another. Investigations ECG: Global changes - PR depression, Saddle shaped (convex) ST elevation Management 1st Line: NSAIDs plus colchicine
191
Myocarditis Background Inflammation of the myocardium, most commonly post-viral. More common in males, and in those < 50 yrs of age May occur in combination with pericarditis. Causes Viral – Coxsackie B, HIV, covid-19 Bacterial – Diphtheria, clostridium Autoimmune disease – SLE
Clinical Features A history of recent viral symptoms (fever, myalgia, headache, sore throat, arthralgia etc). Chest pain Shortness of breath Arrhythmias, palpitations, Investigations ECG: ST segment elevation, T wave inversion Bloods: Elevated CRP + Troponins Management Treat the cause, supportive measures Complications Dilated cardiomyopathy Arrhythmias Heart failure
192
Myxoma Atrial myxoma is the most common primary cardiac tumour. 75% affect the left atrium.
Clinical features Weight loss Pyrexia of unknown origin Clubbing Fatigue Shortness of breath Examination findings: Mid-diastolic murmur with a tumour plop Investigations Echocardiogram: “A pedunculated mass” Figure 192: Atrial Myxoma. The myxoma is the light mass.(arrows) (In this view, the heart is "upside down" - the apex of the heart is at the top and the left atrium is on the bottom left
193
Peripheral Vascular Disease
Key learning Commonly results from atherosclerosis in vessels causing reduced perfusion of limbs Risk factors as for all cardiovascular disease Symptoms progress from intermittent claudication to rest pain to tissue loss ABPI and US arterial duplex identify severity and site of disease Management involves conservatively and pharmacologically modifying cardiovascular risk factors and surgery if above fails All patients given atorvastatin and clopidogrel for life Critical limb ischaemia managed as urgent surgical emergency
194
Pathophysiology of peripheral vascular disease Pain on walking is due to exercise producing an oxygen demand that cannot be met therefore muscles become ischaemia and pain occurs Resting causes collateral system to supply blood to affected muscle and so pain subsides
Fontaine classification outlines natural progression (and symptom severity) Asymptomatic (< 50% stenosis) Intermittent claudication Ischaemic rest pain Tissue loss (ulcers/gangrene)
195
Complications of surgery Peripheral vascular disease
Re-thrombosis Compartment syndrome Reperfusion injury If amputation: Phantom limb pain- manage with gabapentin
196
Risk factors of peripheral vascular disease As for all cardiovascular disease: Smoking Personal or family history of ischaemic heart disease, stroke, vascular disease Diabetes Obesity
Causes Most common- atherosclerosis Buerger’s disease - acute inflammation and thrombosis of lower limb veins/arteries Risk factors- heavy smoking Fibromuscular dysplasia- non-inflammatory artery wall thickening
197
Surgical indications: POVD
Critical limb ischaemia - urgent to prevent limb loss, give IV heparin Pain at rest/night Tissue loss Failed medical management or symptoms limiting lifestyle Surgical options: Endovascular revascularisation (percutaneous transluminal angioplasty +/- stenting) Useful if short stenosis in big vessels Bypass surgery More extensive disease Amputation Last resort Often if gangrene Level of amputation high enough to ensure healing Above knee amputation has worse rehab outcomes than below knee
198
Management of povd Depends on severity and symptoms Ideally should attempt conservative and pharmacological management first before surgical input Conservative: Risk factor modification- Stop smoking, exercise, diet Foot care
Medical: Optimise BP, lipids and DM control All patients with symptomatic PVD: Atorvastatin 80mg OD Clopidogrel 75mg OD If tissue loss Tissue viability to debride/dress Consider antibiotics if wet gangrene
199
Primary Prevention of CVD
Smoking Cessation Pharmacological management options for smoking cessation include: Nicotine replacement therapy Varenicline Mechanism: Nicotine receptor partial agonist Contraindications: Suicidal ideation, depression, pregnancy or breastfeeding Bupropion Mechanism: Nicotinic antagonist, dopamine reuptake inhibitor Adverse effects: Seizures (1/1000) Contraindications: Epilepsy, pregnancy or breast feeding
200
Offer lipid modification (without calculating QRISK) to the following patients: Primary prevention of cvd
Type 1 DM with any of: Age > 40 DM for more than 10 years Established nephropathy Any other RFs for CVD CKD Familial hypercholesterolaemia Lipid modification 1st Line - Atorvastatin 20mg ON If a reduction in non-HDL cholesterol of 40% is not achieved, consider increasing the dose
201
Primary prevention of cvd
Dietary Advice General dietary guidance includes the following.. Fat should contribute to < 30% of total calories 2+ fish per week (1 oily) Salt < 6g 5+ fruit /veg 4-5 portions of unsalted nuts / seeds
202
Primary prevention of cvd
Lipid Modification Qrisk A validated risk stratification tool to calculate a patient's risk of having a heart attack/stroke in the next 10 years https://qrisk.org/ Note - QRISK is not appropriate if there is a history of: Cardiovascular disease CKD Type 1 diabetes mellitus Familial hypercholesterolaemia Age > 85 Qrisk < 10% - Give lifestyle advice and reassess in 5 years Qrisk > 10% - Commence lipid modification (atorvastatin 20mg) + give lifestyle advice
203
Pulmonary Hypertension Management Treat the underlying cause – e.g. group 4 PHTN should be anticoagulated etc. Next, perform acute vasodilator testing (AVT) AVT is performed during right heart catheterisation - to identify patients who may respond well to calcium channel blockers Pulmonary artery pressures are monitored, following the administration of vasodilators including Inhaled nitric oxide, IV epoprostenol/adenosine A positive response is defined by a fall in PA pressure of at least 10mmHg, to below 40mmHg
Pharmacological management Positive response to AVT (minority) – CCBs - nifedipine Negative response to AVT – management options include: Prostacyclin analogues – Iloprost Endothelin receptor antagonists – Bosentan/ ambrisentan Phosphodiesterase inhibitors: Sildenafil Other recommendations Pregnancy is contraindicated in pulmonary hypertension due to a mortality rate of 30-50 %
204
Clinical Features of pulmonary hypertension Symptoms Shortness of breath - Progressive exertional dyspnoea Features of RHF - Peripheral oedema
Examination findings Right (left parasternal) ventricular heave Loud P2 Raised JVP with large A waves Tricuspid regurgitation - Pansystolic murmur (loudest on inspiration) Investigations Echocardiogram Right heart catheterisation to confirm diagnosis
205
Pulmonary Hypertension Background Definition Pulmonary hypertension is defined by a mean pulmonary artery pressure of 25MMHG or more at rest, or 30mmHg on exercise. Increased vascular resistance results in right ventricular failure
Causes & Classification Group 1 PH: Idiopathic – familial pulmonary HTN, HIV, Persistent pulmonary hypertension of the newborn Group 2 PH: PAH with Left sided heart disease Group 3 PH: Respiratory disease – COPD, ILD, OSA Group 4 PH: thromboembolic disease – e.g. PE Group 5 PH: Miscellaneous – sarcoidosis, carcinomatosis etc.
206
207
Tachyarrhythmias Tachyarrhythmia Guidelines ALS tachyarrhythmia guidelines summary: https://www.resus.org.uk/sites/default/files/2021-04/Tachycardia%20Algorithm%202021.pdf
Assessment Step 1: A-E assessment – identify life threatening features: Shock (e.g. Systolic < 90mmHg) Syncope Features of myocardial ischaemia – chest pain Symptoms of severe heart failure – hypoxia, crepitations
208
Management of unstable tachyarrhythmia
If any life-threatening features are present - perform synchronised DC cardioversion (up to 3 attempts). If unsuccessful, prescribe amiodarone 300mg over 20 minutes and repeat the shock.
209
Management of stable tachyarrhythmia If no adverse features are present – treat as stable tachyarrhythmia. Step 1: Differentiate between a broad complex tachycardia (QRS > 120) and narrow complex tachycardia (QRS<120).
Narrow complex tachycardia: Irregular? Probable atrial fibrillation - treat with b-blocker (bisoprolol) or rate limiting calcium channel blocker (Diltiazem) Consider amiodarone or digoxin if there is evidence of HF
210
Narrow complex tachycardia: Regular?
Regular? Step 1: vagal manoeuvres (Valsalva or carotid massage) Step 2: Next give adenosine 6mg Step 3: Then adenosine 12mg Step 4: Then adenosine 18mg Step 5: verapamil or beta blocker
211
Broad complex tachycardia: Irregular?
Probable atrial fibrillation with bundle branch block - b-blocker (bisoprolol) or rate limiting calcium channel blocker (Diltiazem).
212
Regular? Broad complex tachycardia
Regular? Probable VT with pulse – amiodarone 300mg over 10-60 minutes If ineffective perform synchronised DC cardioversion
213
Ventricular tachycardia
VT can be differentiated into: Monomorphic - commonly caused by an MI Polymorphic – including torsades de pointes
214
Common Tachyarrhythmias Paroxysmal SVT Definition: A sudden onset narrow complex tachycardia.
Causes: Atrioventricular nodal re-entry tachycardia (AVNRT) functional re-entry within AV node Atrioventricular re-entry tachycardia (AVRT) anatomical re-entry circuit - e.g. bundle of kent Management: As per ALS guidelines. If recurrent consider b-blockers or radiofrequency ablation.
215
Atrial flutter Definition: Rapid succession of atrial depolarisation (classic sawtooth ECG). Commonly a specified degree of AV block (e.g. 2:1 block describes an atrial rate of 300bpm with a ventricular rate of 150bpm)
Management Rate control– b-blocker/RL-CCB Anticoagulation – as per atrial fibrillation (see below) Definitive management – radiofrequency ablation (most commonly of the tricuspid valve isthmus
216
Atrial fibrillation (AF) Management AF can be managed with a rate control or a rhythm control strategy
Rate control NICE most commonly advocate using a rate control strategy with certain exceptions. 1st line: Beta-blocker (bisoprolol) or RL-CCB (verapamil/diltiazem) Remember to be cautious with B-Bs in asthmatic patients 2nd line: Add a B-blocker/RL-CCB or Digoxin (esp. if HF) Avoid combining bisoprolol with RL-CCB – risk of inducing complete heart block. Rhythm control Indications for consideration of rhythm control strategy: First detected episode Clear and reversible trigger (e.g. pneumonia) Worsening features of HF. Rhythm control of AF can be achieved by pharmacological means or with synchronised (to R wave) electrical cardioversion, with the aim of reverting the patient into sinus rhythm.
217
Anticoagulation CHA2DS2VaSC Score: Actions: Score 0 = No anticoagulation required Score 1 = Consider anticoagulation in men Score 2 = Anticoagulate Nb. If AF + valvular heart disease are co-existent, this is an absolute indication for anticoagulation Anticoagulation: NOAC (apixaban/rivaroxaban etc.) preferred, warfarin (target INR 2-3)
CCF = 1 Hypertension = 1 Age of 75years or more = 2 Diabetes = 1 Previous stroke / TIA or thromboembolism = 2 Vascular disease = 1 Age 65-74 = 1 Sex – Female = 1
218
Bleeding risk
Use ORBIT bleeding risk score (replaced hasbled) – a score of 3 or more suggests “high risk of bleeding”
219
Multifocal Atrial Tachycardia (MAT)
Definition: irregular tachycardia caused by electrical impulses originating from 3 or more different sites in the atria (hence multifocal..). This is identified on the ECG by the presence of 3 morphologically distinct P waves. Management: RL-CCB 1st line
220
Torsades de Pointes Definition: A polymorphic ventricular tachycardia. Often results following severe QTc prolongation - Medical emergency due to the risk of transformation to VF.
ECG: rapid, irregular QRS complexes, appear to be rotating around the ECG baseline Causes of long QTc include: Inherited cardiac disease – long QT syndrome Drugs: antihistamines (Terfenadine), Macrolides – erythromycin/clari, Tricyclic antidepressants (TCAs), Chloroquine Electrolyte abnormalities: Hypocalcaemia, hypokalaemia, hypomagnesaemia Management of TDP: IV Magnesium Sulfate 2g push
221
Wolff-Parkinson White Syndrome Pathology: caused by the presence of a congenital accessory conduction pathway between the atria and ventricles, which can result in episodic tachyarrhythmias including AVRT and AF.
ECG changes: Short PR interval (<120ms) Wide QRS (>110ms) Delta wave – describes a slurred, slow-rising QRS upstroke Management: Radiofrequency ablation of the accessory pathway
222
Valvular Heart Disease Aortic Stenosis Causes
Age > 65 years – degenerative calcification of the aortic valve - most common Age < 65 years – bicuspid aortic valve is the most common Causes include Turner’s syndrome Other causes: Williams Syndrome – supravalvular AS Hypertrophic obstructive cardiomyopathy (HOCM) Examination findings Ejection systolic murmur radiating to the carotids Narrow pulse pressure Slow rising (anacrotic) pulse Soft S2 Management Indications: symptomatic or valvular gradient > 40 – consider valve replacement If not fit enough - consider balloon valvuloplasty or TAVI.
223
Aortic Regurgitation Causes
Valve disease – bicuspid aortic valve, rheumatic heart disease, infective endocarditis Aortic root disease – Marfans, Ehlers Danlos, aortic dissection Examination findings Early diastolic murmur Collapsing pulse Wide pulse pressure De Musset’s (head bobbing), Quinke’s (nailbed pulsation)
224
Mitral stenosis
Causes Rheumatic fever, rheumatic fever, rheumatic fever Clinical Features SOB, pink frothy haemoptysis Examination findings Mid diastolic murmur Opening snap Loud S1 malar flush ECG findings P Mitrale - broad bifid P wave in lead II
225
Mitral Regurgitation Causes
Ischaemic heart disease/post MI MV prolapse, rheumatic fever Examination findings Pansystolic "blowing" murmur which radiates into the axilla Quiet S1 Severe MR - widely split S2 Left ventricular failure
226
Mitral Valve Prolapse
Associated conditions: ADPKD, Marfans Examination findings: Late systolic murmur with mid systolic click
227
Pulmonary stenosis
Examination findings: Harsh ejection systolic murmur which is loudest on inspiration Associated conditions: Carcinoid cancer (flushing, diarrhoea, weight loss)
228
Tricuspid regurgitation Causes
Causes Pulmonary hypertension Infective endocarditis (especially in IVDUs) Examination findings Pansystolic murmur (loudest on inspiration) Left parasternal heave (RVH) JVP: Prominent A waves
229
Prosthetic Heart Valves Biological (bioprosthetic) valves: Bovine or Porcine
Advantages: Long term anticoagulation is NOT needed Lifelong aspirin should be given Disadvantages: Susceptible to degeneration and calcification Hence used in more elderly patients with fewer remaining years of life (> 65yrs)
230
Mechanical valves
Advantages: ‘hard-wearing’ – so less likely to need replacement/repeat surgery Disadvantages: Increased risk of thrombosis – lifelong warfarin is required Aortic valve – target INR 3.0 Mitral valve – INR 3.5
231
Complications of varicose vein
Bleeding- highest risk in large veins over bony prominences subjected to trauma Superficial vein thrombosis- hard and tender over vein DVT Skin ulcers Psychological - low mood due to appearance of varicose veins
232
Management of varicose vein Reassurance in majority of cases Reduce risk factors- weight loss, avoid prolonged sitting/standing Compression stockings if not co-existing arterial insufficiency
Refer to vascular surgery if: Associated pain, swelling, itching Lower limb skin changes Superficial vein thrombosis Active ulceration Interventional options: Endothermal ablation Foam Sclerotherapy Surgery- ligation or stripping of vein
233
Pathophysiology Dilated, tortuous superficial veins Most commonly in legs Indicate venous insufficiency- commonly incompetent valves in affected vein causing reflux of blood Epidemiology Affect a third of population More common with age and in females
Risk factors Family history Pregnancy Prolonged sitting or standing History of DVT Examination findings 1.Examine standing and lying down 2,Varicose veins- 3mm + in diameter when standing 3.Assess for chronic venous insufficiency- skin hyperpigmentation, venous eczema, lipodermatosclerosis, atrophie blanche 4.Assess for complications- see below Investigations Further imaging only if concerned: USS for DVT
234
Varicose vein
Varicose Veins Key learning Dilated, tortuous superficial veins Most commonly cosmetic concern but can cause symptoms and complications Indicate venous insufficiency Risk factors include obesity, pregnancy and prolonged standing/sitting Clinical diagnosis Referral to vascular surgeons only if causing symptoms or complications (skin changes, ulcers, superficial vein thrombosis)
235
236
237
238